Evogene (EVGN) Beginning Cash Balance (2013 - 2026)

Over the twelve months ended Mar 31, 2026, Evogene's Beginning Cash Balance came in at $34.41 million, down 28.3% year-over-year; for the year ended Dec 31, 2025, it was $15.3 million, down 26.3% from the prior year.

• Beginning Cash Balance has declined for four consecutive years, with a five-year compound annual growth rate of -15.1% (years ended Dec 2020 to Dec 2025).
• By year, Beginning Cash Balance came in at $20.77 million in the year ended Dec 31, 2024 (-28.3%), $28.98 million in the year ended Dec 31, 2023 (-10.3%), $32.33 million in the year ended Dec 31, 2022 (-30.1%) and $46.23 million in the year ended Dec 31, 2021 (+33.0%).
• Five-year quarterly Beginning Cash Balance spans a low of $5.63 million in the quarter ended Dec 31, 2025 and a high of $42.76 million in the quarter ended Sep 30, 2021.
• Year over year, Beginning Cash Balance has now declined in each of the last four quarters, with an average decline of 39.3% over the last seven quarters.
• The high point for year-over-year Beginning Cash Balance in five years was the quarter ended Sep 30, 2021 (growth of 37.6%); the low point was the quarter ended Dec 31, 2024 (a decline of 58.6%).
• Per Business Quant data, the three quarters before the quarter ended Mar 31, 2026 came in at $5.63 million (quarter ended Dec 31, 2025), $8.33 million (quarter ended Sep 30, 2025) and $7.5 million (quarter ended Jun 30, 2025).